Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.98 |
| ▸ | ABL1 | P00519 | 17/20 | 0.76 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.76 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 14/20 | 0.76 |
| ▸ | PRKDC | P78527 | 14/20 | 0.76 |
| ▸ | EGFR | P00533 | 13/20 | 0.76 |
| ▸ | HCK | P08631 | 13/20 | 0.76 |
| ▸ | KDR | P35968 | 13/20 | 0.76 |
| ▸ | MTOR | P42345 | 13/20 | 0.76 |
| ▸ | EPHB4 | P54760 | 13/20 | 0.76 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.76 |
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14574629 | 1.00 | SRC (0.98) | SRCABL1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL7508684 | 0.89 | SRC (0.78) | SRCABL1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL14574603 | 0.88 | SRC (0.76) | SRCABL1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL409057 | 0.86 | SRC (1.00) | SRCABL1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL14574624 | 0.86 | SRC (0.74) | SRCABL1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL29390196 | 0.86 | SRC (1.00) | SRCABL1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL12437092 | 0.86 | SRC (1.00) | SRCABL1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL3630418 | 0.85 | SRC (0.76) | SRCABL1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL18196381 | 0.85 | SRC (0.80) | SRCABL1PIK3CDPIK3CAPIK3CG | |
| SCHEMBL29388059 | 0.84 | SRC (0.71) | SRCABL1PIK3CDPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | PNCK, TXK, CILK1 | SRC 132/4885ABL1 1181/4885PIK3CD 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.